Genetic testing company 23andMe has agreed to sell itself to a nonprofit led by co-founder Anne Wojcicki.
After a cyberattack in 2023, 23andMe filed for bankruptcy in March. Former CEO Wojcicki resigned to bid for the company, but pharmaceutical company Regeneron made a $256 million offer.
Wojcicki’s nonprofit TTAM Research Institute made a higher bid of $305 million, leading to the acquisition announcement. Customers will be informed of the deal at least two days before closing, with privacy policies remaining intact.
Tech and VC heavyweights join the Disrupt 2025 agenda
Approval from the bankruptcy court is still pending, facing legal challenges from state attorneys general objecting to the sale of genetic data without consent. A privacy ombudsman raised concerns about 23andMe’s privacy policies and consumer trust in light of the acquisition.
